5-2020


Kristen A. Russ

Steven J. Holochwost

Susan M. Perkins

Kristin Stegenga
Children's Mercy Hospital

Seethal A. Jacob

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Part of the Hematology Commons, and the Pediatrics Commons

Recommended Citation

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Creator(s)
Kristen A. Russ, Steven J. Holochwost, Susan M. Perkins, Kristin Stegenga, Seethal A. Jacob, David Delgado, Amanda K. Henley, Joan E. Haase, and Sheri L. Robb
Cortisol as an Acute Stress Biomarker in Young Hematopoietic Cell Transplant Patients/Caregivers: Active Music Engagement Protocol

Kristen A. Russ, PhD,1 Steven J. Holochwost, PhD,2 Susan M. Perkins, PhD,3,4 Kristin Stegenga, PhD, RN, CPON,5 Seethal A. Jacob, MD, MS, FAAP,3,6 David Delgado, MD,7 Amanda K. Henley, MM, MT-BC,8 Joan E. Haase, PhD, RN, FAAN,8 and Sheri L. Robb, PhD, MT-BC8

Abstract

Objective: Primary aims of the proposed protocol are to determine the feasibility/acceptability of the active music engagement intervention protocol during hematopoietic stem cell transplantation (HSCT) and clinical feasibility/acceptability of the biological sample collection schedule.

Design: The authors propose a single-case, alternating treatment design to compare levels of child and caregiver cortisol in blood and saliva collected on alternating days, when the dyad receives and does not receive AME sessions. Included are the scientific rationale for this design and detailed intervention and sample collection schedules based on transplant type.

Setting/Location: Pediatric inpatient HSCT unit.

Subjects: Eligible participants are dyads of children 3–8 years old, hospitalized for HSCT, and their caregiver. Children with malignant and nonmalignant conditions will be eligible, regardless of transplant type.

Intervention: AME intervention is delivered by a board-certified music therapist who tailors music-based play experiences to encourage active engagement in, and independent use of, music play to manage the interrelated emotional distress experienced by children and their caregivers during HSCT. Dyads will receive two 45-min AME sessions each week during hospitalization.

Outcome Measures: Eight collections of blood (child) and saliva (child/caregiver) will be performed for cortisol measurement. The authors will also collect self-report and caregiver proxy measures for dyad emotional distress, quality of life, and family function. At study conclusion, qualitative caregiver interviews will be conducted.

Results: Planned analyses will be descriptive and evaluate the feasibility of participant recruitment, cortisol collection, planned evaluations, and AME delivery. Analysis of qualitative interviews will be used to gain an understanding about the ease/burden of biological sample collection and any perceived benefit of AME.

Conclusions: Behavioral intervention studies examining biological mechanisms of action in pediatric transplant populations are rare. Findings will provide important information about the feasibility/acceptability of the proposed protocol.
of collecting cortisol samples during a high-intensity treatment and advance understanding about the use of active music interventions to mitigate child/caregiver distress during the transplant period.

**Keywords:** biomarker, cortisol, stress, music therapy, pediatric, hematopoietic stem cell transplant

**Introduction**

**Hematopoietic stem cell transplantation (HSCT)** is the curative therapy of choice for many malignancies that require high-dose chemotherapy, and sometimes radiation therapy, and the only curative therapy option for some nonmalignant conditions such as hemoglobinopathies. Regardless of diagnosis, HSCT is an intense complex treatment with many risks. Young children undergoing HSCT and their caregivers are at particular risk for heightened emotional distress, which is associated with physical symptom distress and diminished quality of life and family function. In addition, this acute emotional distress is related to traumatic stress symptoms after treatment. Despite evidence that young child and caregiver distress is inter-related, few interventions have been developed to address this shared distress and fewer specific to transplants. This acute phase of HSCT, which is a high-intensity treatment requiring 3–6 weeks of hospitalization. In addition, to expand the understanding about how active music interventions work to mitigate transplant-related stress, the authors will also explore the feasibility/acceptability of collecting the stress biomarker, cortisol, from children and caregivers.

Evidence that increased hypothalamic–pituitary–adrenal (HPA) axis activity stimulates the release and production of inflammatory biomarkers, which in turn is associated with negative health outcomes for individuals undergoing treatment for chronic conditions and caregivers, supports investigation of biological pathways underlying the use of active music to mitigate transplant-related stress. Cortisol is a steroid hormone secreted by the HPA axis in response to acute and prolonged stress, and assaying various bodily fluids for cortisol is a widely used method of indexing HPA axis activity in children. To date, few intervention studies have looked at cortisol in pediatric patients with malignant and nonmalignant conditions, and of those, only one used music and none involved children and caregivers. This is likely due to challenges associated with cortisol collection and interpretation during cancer and HSCT treatment and difficulties conducting fully powered, randomized intervention trials in low-incidence populations. To overcome these challenges, the authors propose a single-case design study, which allows for estimation of intervention effects in small samples drawn from low-incidence populations.

The authors’ primary aims are to determine the feasibility/acceptability of the AME intervention protocol during HSCT and evaluate clinical feasibility/acceptability of the schedule for biological samples required when using a single-case design. If the authors meet feasibility thresholds for blood and salivary cortisol (collection and sample quantity/quality), they will examine changes in parent and child cortisol levels relative to the AME intervention. The secondary aim is to examine the feasibility of completing self-report measures used in prior AME studies in the context of HSCT. This secondary aim will also establish whether it is feasible/acceptable to collect both biological and self-report data during a high-intensity treatment in subsequent trials. Areas of evaluation include activities/timelines related to recruitment, blood and salivary cortisol collection, planned evaluations, and intervention delivery. Specific research questions are as follows:

1. What percentage of eligible child/caregiver dyads consent to study participation?
2. What percentage of AME sessions do child/caregiver dyads complete?
3. What percentage of planned measures [other than cortisol] do caregivers complete?
4. What percentage of planned cortisol samples are collected and what percentage of these samples yield usable data?
5. What are caregivers’ perspectives about the relative ease/burden of biological sample collection, benefit (or nonbenefit) of AME for managing distress, and enhancing family and quality of life outcomes for self and child?

**Materials and Methods**

**Conceptual framework**

The conceptual framework (Fig. 1) is based on Robb’s Contextual Support Model of Music Therapy and further informed by Kazak’s Pediatric Medical Traumatic Stress Model, which provides a useful heuristic for understanding short- and long-term consequences of HSCT treatment for children and caregivers. In this framework, recurring events related to HSCT (i.e., hospitalization, symptom distress, and procedures) are viewed as potentially traumatic events. Caregiver appraisal of events as traumatic or not traumatic is influenced by pre-existing factors, which serve as antecedents. Research indicates that higher child and caregiver distress during HSCT is related to (1) demographics (younger child/caregiver age, female caregiver gender, and lower socioeconomic status/education), (2) higher caregiver/child distress with prior hospitalizations and greater traumatic stress symptoms, and (3) disease and treatment characteristics (diagnosis and transplant type).
The AME is designed to directly target potential proximal mediators of child engagement and caregiver–child interaction, as well as distal mediators of perceived family normalcy, caregiver confidence (self-efficacy) about their ability to support their child during treatment, and independent music play between therapist-led sessions. Outcomes include child outcomes (emotional distress, physical symptom distress, cortisol, and quality of life), caregiver outcomes (emotional distress, traumatic stress symptoms, cortisol, and quality of life), and family function.

Study design and rationale

In this one-group pilot study (Fig. 2), approved by the Indiana University Institutional Review Board, children and their caregivers will receive two 45-min AME sessions each week during the acute phase of HSCT until time of discharge (i.e., two sessions/week for duration of treatment). Session frequency and duration were selected based on preliminary studies and HSCT symptom trajectory. The total number of sessions will be based on the individual child’s admission period to account for variations in treatment duration, to mimic standard care, and to avoid removal of AME as a supportive care service before discharge when children and caregivers still require support. The authors anticipate that a majority of patients will receive six sessions, over a 3-week period, and to collect data on the number of sessions each dyad receives to inform analysis and interpretation of findings.

Single-case designs were developed to facilitate examination of treatment when data can only be collected from a small number of individuals, such as when investigating different approaches to behavior modification among individuals with rare developmental disabilities. Using the single-case alternating treatment design, the authors compare levels of cortisol in blood and saliva samples collected from dyads on days when they receive AME sessions with levels of cortisol on days when they do not receive AME. Since relatively few children receive HSCT, the single-case design is ideal for evaluating interventions during transplants. The essential logic of the single-case design, as implemented in this study, is that levels of cortisol will be consistently and clearly lower on days when dyads receive AME than on days when they do not. If the analyses, as described below, reveal that this is the case, the authors may infer that AME caused observed reductions in cortisol.

Participants and recruitment

Children/caregivers will be study eligible if the child (1) is 3–8 years of age (inclusive) at the time of enrollment; (2) will receive inpatient HSCT for a malignant or nonmalignant condition, including hemoglobinopathies; and (3) has one caregiver who agrees to be present for all sessions. Children/caregivers will not be eligible if (1) the caregiver or child does not speak English or (2) if the child has a significant cognitive impairment that may hinder their ability to participate, as determined by consultation with the attending HSCT physician, primary hematologist–oncologist, and caregivers. Eligibility will not be dependent on transplant type (autologous or allogeneic).

The authors will enroll children, ages 3–8 years, admitted for HSCT and one caregiver (i.e., parent or legal guardian). 

---

**FIG. 1.** Conceptual framework. AME, active music engagement; ESAS, Edmonton Symptom Assessment System; PCL-S, PTSD checklist; PIES, Prior Illness Experiences Scale.
as dyads. The targeted sample size is four child–caregiver dyads, which will provide the information needed to determine the feasibility/acceptability of study procedures and refine intervention content. Certified research coordinators will use an eligibility checklist to identify potential participants, and a study team member will provide study information, verify eligibility, and obtain written caregiver consent/assent for children ≥7 years.

Active music engagement intervention

Dyads will receive two 45-min AME sessions in private rooms at the HSCT unit each week for the duration of their inpatient stay. AME sessions were designed for delivery by a board-certified music therapist (MT-BC) who tailors music-based play experiences to encourage active engagement in and independent use of music play as a strategy to manage distress.19–21 During sessions, the MT-BC provides dyads repeated opportunities to experience competence, autonomy, and meaningful interactions through music-based play activities and provides support/education about ways that children/caregivers can use music play to manage distress and sustain a sense of family normalcy while being hospitalized and following HSCT discharge. AME has three primary components: (1) therapist-led music-based play activities and sessions, (2) a music play resource kit (to promote independent music play), and (3) session planning and caregiver tip sheets that focus on ways to use music play during hospitalization and as dyads transition from hospital to home (Table 1).

Biological sample collection

The authors developed two sampling schedules based on transplant type (Figs. 3 and 4) to address differences in conditioning treatment protocols for autologous and allogeneic transplants and to avoid periods of treatment with corticosteroids, which can interfere with cortisol measurements. Biological samples collected will include blood (child) and saliva (child and caregiver). Blood (1 mL) will be collected from the child’s central line as part of daily transplant laboratories (drawn 4–6 AM). The blood, in rapid serum tubes, will be sent immediately to the pathology laboratory for cortisol analysis using a Beckman Coulter UniCel DxI800 immunoassay system. Saliva will be collected from the child and caregiver by study staff at three different time points on each collection day: (1) up to 1 h before the AME session, (2) up to 1 h after the session, and (3) 1–3 h after the second collection. To collect saliva, the child and caregiver will be instructed to drool into 50-mL conical tubes until ~500 μL of saliva is collected. The saliva will be immediately stored on dry ice and transferred to −80°C until analysis. Salivary cortisol levels will be measured using an R&D Systems cortisol parameter assay. For child participants, the authors will capture medical record data on any medications that can affect cortisol levels. In addition, caregivers will complete a questionnaire (for self and child) about activities or substances known to affect cortisol levels (e.g., sleep, exercise, and caregiver medications) and timings/details of food intake.45

For this single-case design, the authors will also collect biological measures on treatment and nontreatment days, controlling for time of day (to account for daily fluctuations.
in cortisol) and potential order effects. As seen in Figure 3, the sampling schedule for autologous transplants includes eight collections (4 treatment days and 4 control days). The first four collections occur during conditioning for the transplant; and the remaining four occur post stem cell infusion. Note that the first collection serves as the baseline for autologous participants. Treatment and control days are linked (they occur 1 day apart and take place at the same time of day), with four linked collections scheduled over the course of the transplant.

The sampling schedule for allogeneic transplants (Fig. 4) is similar; however, the timing of collection is adjusted to account for drug interference that occurs during conditioning. Because allogeneic collections occur later in treatment, the authors will collect baseline blood samples during a routine clinic visit 1 week before admission. In addition, before side effects (e.g., mucositis) occur, the authors will schedule two practice collections to help children learn how to give saliva samples. In both transplant regimens, the number of collections exceeds the recommended number of three data points per condition established for single-case designs.46

<table>
<thead>
<tr>
<th>Intervention component</th>
<th>Component 1: Music-Based Play Activities</th>
<th>Component 2: Music Play Resource Kit</th>
<th>Component 3: Session Planning and Caregiver Tip Sheets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theoretical principles</td>
<td>(1) Predictable environment provides a structure that supports child competence. Therapist uses familiar music activities to provide structure and increase child’s ability to predict what will happen in their environment. (2) Leveled activities help ensure success and support child competence. Therapist tailors physical activity requirements to meet the individual needs of each child. Enables child success and engagement during periods of high or fluctuating symptom distress. (3) Opportunities to make independent decisions support child autonomy. Children choose from a variety of music play activities, and each activity includes a wide range of materials. Activities include a wide range of materials and activity options so that the child can make choices for self and others. Therapist uses improvisational techniques to follow child-initiated changes in their music making (e.g., child changes tempo or style of playing). (4) Activities structured to support caregiver–child interaction. Activities structure and support reciprocal caregiver–child interactions. The therapist individualizes experiences to support increased frequency and quality of interactions. Supports independent use of music play to manage distress between therapist-led sessions. Activities mirror content from therapist-led sessions. The kit includes: (1) Professional CD recording of music composed and/or arranged specifically for the AME intervention. (2) Age-appropriate musical instrument and play materials that correspond to each activity. (3) Activity cards designed to give children/caregivers at-a-glance information on ways they can use their kit. (1) Promotes caregiver competence about how children use play to cope and ways to engage their child in music play during the transplant period. (2) Promotes caregiver autonomy by empowering caregivers with skills/resources to support their child during treatment. (3) Supports caregiver–child relationships through normalizing music-based play activities.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AME, active music engagement.

Caregiver report measures

Caregivers will complete self-report and caregiver proxy questionnaires at four time points (Table 2). Baseline measures will be completed during a routine clinic visit, within 30 days of the child’s scheduled HSCT admission. Time 2 measures will be completed post-AME session eight, Time 3 measures at the time of discharge (if discharge did not occur at time of session eight), and Time 4 measures at 100 days post-transplant during a subsequent clinic visit. In addition, caregivers will complete brief pre/postsession measures for caregiver distress/child symptom distress at sessions 2, 4, and 6. All measures will be administered by trained evaluators not involved with AME delivery, and all evaluation sessions audio-recorded for quality assurance monitoring. The authors selected questionnaires based on the study’s theoretical framework (Fig. 1), with careful consideration of psychometric properties, sensitivity to change, and response burden. Table 2 provides a list of all measures, including psychometrics and administration schedule.47–53

Caregiver qualitative interviews

The authors will conduct semistructured qualitative interviews with caregivers to identify any changes that may be required for AME delivery during HSCT and evaluate acceptability of study activities/timelines related to biological sample collection, planned evaluations, and intervention delivery. Interviews will begin with an open-ended question to capture overall perceptions of the caregiver’s experience (i.e., “Please tell me about your experience of participating in the
FIG. 3. Autologous transplant biological sample collection timetable.
FIG. 4. Allogeneic transplant biological sample collection timetable.
Follow-up questions will include specific questions about the perceived benefit (or nonbenefit) of AME in managing stress, experiences with saliva collection, and the value of different intervention components (i.e., tip sheets, goal setting worksheet, and kit use). Interviews will occur within 2 weeks of Time 2 data collection (in the hospital or by phone). Trained personnel, not involved in AME delivery, will conduct audio-recorded interviews for subsequent transcription and analysis.

**Data analysis plan**

The following analysis includes a systematic plan to address primary and secondary aims of the proposed pilot

### Table 2. Measures

<table>
<thead>
<tr>
<th>Variable(s)</th>
<th>Measure</th>
<th>No. of items</th>
<th>Reliability evidence</th>
<th>Admin. schedule</th>
<th>Completed by</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antecedent factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parent/child age, parent gender, SES, parent education</td>
<td>Family Information Form</td>
<td>3</td>
<td>N/A</td>
<td>T1</td>
<td>Parent</td>
</tr>
<tr>
<td>Prior distress w/hospitalization</td>
<td>Prior Illness Experiences Scale</td>
<td>13</td>
<td>0.78&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1</td>
<td>Parent</td>
</tr>
<tr>
<td>Parent/child</td>
<td>Abbreviated PTSD Checklist (PCL-S)</td>
<td>6</td>
<td>0.94&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1, T2, T3, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Disease characteristics</td>
<td>Diagnosis and Treatment Form</td>
<td>2</td>
<td>N/A</td>
<td>T4</td>
<td>Research Assistant (RA)</td>
</tr>
<tr>
<td>Treatment characteristics</td>
<td>Medication Data Form</td>
<td>N/A</td>
<td>N/A</td>
<td>T1, T2, T3, T4</td>
<td>RA</td>
</tr>
<tr>
<td>Proximal mediators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Child engagement</td>
<td>Behavioral Coding Form</td>
<td>N/A</td>
<td>0.85&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Sessions 2, 4, 6</td>
<td>Trained Coder</td>
</tr>
<tr>
<td>Parent–child interaction</td>
<td>Behavioral Coding Form</td>
<td>N/A</td>
<td>0.85&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Sessions 2, 4, 6</td>
<td>Trained Coder</td>
</tr>
<tr>
<td>Distal mediators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family normalcy perspective</td>
<td>Family Management Measure</td>
<td>14</td>
<td>0.90&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1, T2, T3, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Parent self-efficacy</td>
<td>Parental Beliefs Scale</td>
<td>20</td>
<td>0.85&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1, T2, T3, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Parent report</td>
<td>Parent Report</td>
<td>2</td>
<td>N/A</td>
<td>Sessions 2–6; T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Child outcomes</td>
<td>CHQ—Mental Health Subscale</td>
<td>16</td>
<td>0.81&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1, T2, T3, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Child physical symptom distress</td>
<td>Edmonton Symptom Assessment System</td>
<td>5</td>
<td>0.69–0.80&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>(mood, anxiety, pain, fatigue, nausea)</td>
<td></td>
<td></td>
<td></td>
<td>Sessions 2, 4, 6</td>
<td>Parent</td>
</tr>
<tr>
<td>Child quality of life Neurophysiological indicator of stress</td>
<td>KINDL&lt;sup&gt;R&lt;/sup&gt;</td>
<td>20</td>
<td>0.89&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1, T2, T3, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Parent outcomes</td>
<td>Profile of Mood States-Short Form</td>
<td>37</td>
<td>0.99&lt;sup&gt;c&lt;/sup&gt;</td>
<td>T1, T2, T3, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Parent emotional and traumatic stress symptoms</td>
<td>Impact of Events Scale-Revised (IES-R)</td>
<td>22</td>
<td>0.84–0.91&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1, T2, T3, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Parent distress (mood, anxiety, fatigue)</td>
<td>Edmonton Symptom Assessment System</td>
<td>3</td>
<td>0.69–0.80&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Parent quality of life Neurophysiological indicator of stress</td>
<td>Index of Well-being</td>
<td>9</td>
<td>0.93&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1, T2, T3, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Parent/child outcomes</td>
<td>FACES II</td>
<td>30</td>
<td>0.90&lt;sup&gt;a&lt;/sup&gt;</td>
<td>T1, T2, T3, T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Qualitative interviews</td>
<td>Parent Interview</td>
<td>N/A</td>
<td>N/A</td>
<td>T4</td>
<td>Parent</td>
</tr>
<tr>
<td>Parent acceptability</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Cronbach’s z.

<sup>b</sup>Inter-rater reliability.

<sup>c</sup>Correlation with POMS.

FACES, Family Adaptability and Cohesion Evaluation Scale; POMS, Profile of Mood States.

music play sessions with your child.”). Follow-up questions will include specific questions about the perceived benefit (or nonbenefit) of AME in managing stress, experiences with saliva collection, and the value of different intervention components (i.e., tip sheets, goal setting worksheet, and kit use). Interviews will occur within 2 weeks of Time 2 data collection (in the hospital or by phone). Trained personnel, not involved in AME delivery, will conduct audio-recorded interviews for subsequent transcription and analysis.

**Data analysis plan**

The following analysis includes a systematic plan to address primary and secondary aims of the proposed pilot
study. Descriptive statistics will be computed for all variables to ensure data quality.

Research questions 1–3. Analyses will be descriptive. The authors will report the percentage of (1) eligible caregiver/child dyads who consent to study participation (feasibility threshold = 75%) and reasons that eligible dyads decline study participation, (2) planned intervention activities that dyads complete (acceptability threshold = 75%) and reasons for canceled, rescheduled, and missed sessions, and (3) planned measures that caregivers complete at Time 1, Time 2, Time 3, and Time 4 data collections (feasibility threshold = 75%), including examination of missing data patterns.

Research question 4. Analyses will be descriptive. In the first portion of these analyses, the authors will report the percentage of cortisol samples collected from children (feasibility threshold = 75%) and caregivers (feasibility threshold = 85%). In the second portion, the authors will report the proportion of samples judged to be of sufficient quality for further analyses, such that cortisol values fall within the range for which the assay has been validated as well as the distribution of values collected from other children and caregivers across the study. Given the potential for children’s samples to be altered by ingestion of food, drink, or medication, the authors will establish a lower feasibility threshold for children (60%) than for their caregivers (75%).

Research question 5. The authors will use a qualitative descriptive design with content analysis to analyze interview data. Procedures include (1) interviews transcribed and reviewed for accuracy; (2) category development through content analysis; and (3) findings validated by peer review to reach consensus.

Biomarker analysis plan

Assuming that the feasibility thresholds specified above are met, blood and salivary cortisol levels will be graphed to visualize trends. To complement the results of these visual analyses, the authors will compute Tau-U statistics. The Tau-U statistic is a nonoverlap metric derived by comparing all unique pairs of data points (here, cortisol levels) between the treatment and control conditions. Before analysis, data will be inspected for linear trends indicative of serial conditioning effects. These effects may occur when cortisol levels measured at points in the intervention are subject to the current and prior effects of the intervention. If conditioning effects are detected, the calculation of the Tau-U statistic will be adjusted for linear trends using utilities embedded in the Tau-U calculator. The Tau-U statistics will then be used to estimate an effect size for the treatment on levels of cortisol for each participant and for the sample as a whole.

Discussion

Importance

Pediatric HSCT has proven to be an effective treatment for many pediatric malignancies as well as certain nonmalignant hematologic conditions. Advances in conditioning regimens and donor options have also expanded to populations for whom HSCT can be beneficial, including metabolic disorders, immunodeficiencies, and even inflammatory bowel disease. While it is encouraging that HSCT is a therapeutic option for increasing numbers of otherwise incurable diseases, HSCT also raises concern that more children and caregivers will endure significant stress associated with the transplant and will need greater availability and variety of supportive care options. AME, as described in this protocol, not only provides support to the child and caregiver during the acute period of HSCT but also builds coping skills after HSCT when psychosocial concerns such as traumatic stress symptoms emerge. Because HSCT is a complex treatment, an important aspect of this study is to ensure that AME and study-related activities do not interfere with planned treatment protocols, thereby avoiding creation of undo stress for the treatment team and child–caregiver dyads. As such, this study represents an important step for refining AME for delivery during HSCT and advancing the understanding about the use of active music interventions to manage acute stress for this growing patient population.

Method strength

Conventional research designs (e.g., randomized control trials) require relatively large samples to assess treatment effects; however, as previously noted, single-case designs were developed for use in contexts where data can be collected from only a small number of individuals. Applying a single-case design to the study of HSCT will allow estimation of the effects of AME on an understudied population of children. Moreover, by collecting cortisol levels at multiple time points, it will be possible to isolate AME effects on different aspects of HPA axis activity (i.e., waking cortisol levels, baseline levels, or diurnal cortisol throughout the day) by comparing levels of cortisol that correspond to different aspects of HPA axis activity on treatment and control days. Additionally, hospitalization will provide a controlled environment where medical records can be used to identify events that may contribute to unexpected fluctuations in cortisol levels, allowing for more accurate data interpretation.

Potential limitations

For children with malignant disease requiring HSCT, there may be long-term effects of therapy on the HPA axis. This may create difficulties in interpretation of patient cortisol levels and the potential clinical benefit of AME. Collection of baseline cortisol may be useful in differentiating between long-term treatment effects and the effects of AME. Additionally, HSCT-related side effects, such as pain associated with mucositis or general malaise, might result in patients choosing not to provide a biological sample. Finally, the inability of consenting caregivers to be present for all AME sessions and saliva collections due to work or other caregiver responsibilities may result in missed collections. This study will provide important information about the feasibility/acceptability of collecting cortisol samples at the frequency required for single-case design from young
children and caregivers during a high-risk high-intensity treatment. In addition, findings will advance the understanding about the use of active music interventions to mitigate the inter-related distress experienced by children and caregivers during the transplant period.

Author Disclosure Statement

S.A.J. has received an honorarium for a speaking engagement from Novartis. For all other authors, no competing financial interests exist.

Funding Information

The authors would like to acknowledge the funding received from the Center for Enhancing Quality of Life (CEQL)—Indiana University School of Nursing, the IU Simon Cancer Center P30 Support Grant (P30CA082709), and the Class of 1964 Pilot Research Fund—Indiana School of Nursing. The authors would also like to acknowledge the Indiana University Melvin and Bren Simon Cancer Center Translational Research Core for assistance in developing the biological sample collection protocol.

References


Address correspondence to:
Sheri L. Robb, PhD, MT-BC
Indiana University School of Nursing
600 Barnhill Drive, NU E433
Indianapolis, IN 46202
USA
E-mail: shrobb@iu.edu